Second-line NSCLC treatment proven to prolong survival
A National Cancer Institute of Canada, double-blind, placebo-controlled Phase III trial evaluated Tarceva 150-mg monotherapy, randomized 2:1 versus placebo in second- and third-line patients with Stage IIIB or IV NSCLC. [1,2]
The results were:- Tarceva significantly prolonged overall survival by 37% (P=0.001): [1]
- median survival lengthened by 42.5%
- one-year survival increased by 45%
- In the second-line treatment of patients with PS 0–1, Tarceva significantly prolonged overall survival by 47% (P=0.018): [3]
- median survival was 9.4 months with Tarceva vs 6.7 months with placebo
- Tarceva significantly prolonged progression-free survival by 64%. [2]
- Tarceva significantly prolonged progression-free survival in second-line
PS 0–1 patients by 79%. [3] - Tarceva demonstrated significant symptom benefits by prolonging time to progression of symptoms that affect quality of life. [1,3]
With a unique mechanism of action different from conventional chemotherapies, Tarceva was proven effective in diverse patient populations. [1,3,4]
Second-line treatment with Tarceva offered patients a proven survival advantage and an established tolerability profile combined with the ease of oral administration. [1,3]
In the second-line treatment of NSCLC, Tarceva can help prolong your patient’s lifeline. [1,3]
